June 23 (UPI) -- Novo Nordisk announced Monday it has ended its partnership with Hims & Hers over its sale and promotion of cheaper versions of its weight loss drug Wegovy.
The company said in a press release that Hims & Hers failed to follow law "prohibiting mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
"We expected that the efforts towards compounding personalization would diminish over time. When we didn't see that, we had to make a choice on behalf of patients," said Dave Moore, Novo Nordisk's executive vice president of U.S. operations.
An investigation found that the drugs sold were manufactured by foreign suppliers in China and the FDA never authorized or approved the processes used by any foreign suppliers, according to a report from the Brookings Institute.
Related
